Fwd: US Pharma and Biotech Summit 2026: agenda highlights tailored for you

[Amali De Silva - Mitchell]

They contacted us to be a sponsor

---------- Forwarded message ---------
From: FT Live <ftl...@mail.live.ft.com>
Date: Mon, Apr 13, 2026, 10:08
Subject: US Pharma and Biotech Summit 2026: agenda highlights tailored for you
To: <gphli...@gmail.com>

Where demand and opportunity are emerging

 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

Presented by In collaboration with May 14 | In-Person & Digital | Convene One Liberty Plaza, New York US Pharma and Biotech Summit Your clients are changing how they invest, partner and operate. This agenda highlights where priorities are shifting, from AI and data to new commercial models, so you can better understand where you fit and where opportunities are opening up. Join us to understand where your clients are heading, and where you can add the most value. Register now Download the brochure Top sessions: Dealmakers’ dialogue: Value and volume in biopharma M&A, IPOs and alliances Biopharma dealmaking is showing signs of renewed momentum, with factors such as the looming patent cliff helping to drive targeted M&A activity. Increasing the volume of larger acquisitions depends on big pharma’s strategic priorities and appetite for risk in an unsettled geopolitical and economic environment. Clive Meanwell, Chairman and Partner, Population Health Partners Eric Tokat, Co-President of Investment Banking, Centerview Partners Graham Robinson, M&A partner, Kirkland & Ellis Elizabeth Naldi-Jacob, Vice President, Business Development & Licensing, Head, HQ Transactions & Corporate Development, Merck Oliver Barnes, US deals & activism correspondent, Financial Times AI in pharma – time to deliver  After several years of hype, money and model-building, pharma and biotech companies are under pressure to show meaningful returns on investment in AI. 2026 will be a year to see if they can prove their promises. Susan Fitzpatrick-Napier, CEO, TrialWire Fiona Marshall, President, Biomedical Research, Novartis Tala Fakhouri, Vice President Consulting, AI & Digital Policy, Real-World Research, Parexel Richard Bonneau, Vice President and Global Head, AI for Drug Discovery, Genentech Wearables, apps and the surge of health data Consumer technology is bleeding into healthcare. Wearable devices that monitor biometrics and apps that claim to treat and track health conditions are growing in popularity. But health data must be managed with care. Calum MacRae, Professor, Harvard Medical School David Benshoof Klein, CEO, Click Therapeutics Ricky Bloomfield, Chief Medical Officer, Oura Lydia Ramsey Pflanzer, Deputy Editor, Endpoints News Register now Explore the agenda In partnership with   Global knowledge partner Strategic partners Lead sponsors Associate sponsors Manage the emails you ...   © THE FINANCIAL TIMES LTD 2026 We use pixels in HTML emails to tell us if the email opened or links in it are clicked on. The pixel will be deleted if you delete the email. See our cookie policy for more information. This email was sent by a company owned by Financial Times Group Limited (FT Group), registered office at Bracken House, 1 Friday Street, London, EC4M 9BT. Registered in England & Wales with company number